Italia markets closed
Dow Jones
38.771,60 +182,44 (+0,47%) Nasdaq
17.903,68 +214,80 (+1,21%) Nikkei 225
38.102,44 -712,12 (-1,83%) EUR/USD
1,0737 +0,0028 (+0,26%) Bitcoin EUR
62.224,94 +193,34 (+0,31%) CMC Crypto 200
1.397,60 +9,44 (+0,68%)
NBIX Sep 2024 140.000 call
OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
In data: 02:32PM EDT. Mercato aperto.
| Chiusura precedente | 11,40 |
| Aperto | 11,30 |
| Denaro | 9,60 |
| Domanda | 12,10 |
| Prezzo d'esercizio | 140,00 |
| Scadenza | 2024-09-20 |
| Min-Max giorno | 11,30 - 11,40 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | 1,02k |
GlobeNewswireSosei Heptares’ partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults
NBI-1117570 is an investigational, oral, muscarinic M1/M4 selective dual agonist discovered by Sosei Heptares that may have the potential to treat neurological and neuropsychiatric conditionsNBI-1117570 is the second compound to advance into clinical development from a portfolio of selective muscarinic receptor agonists licensed by Sosei Heptares to Neurocrine following NBI-1117568, an oral, selective muscarinic M4 receptor agonist, which is in Phase 2 clinical trials as an investigational treat
© 2024 Yahoo. Tutti i diritti riservati.